• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.意大利散发性原发性甲状旁腺功能亢进症管理指南。
Endocr Metab Immune Disord Drug Targets. 2024;24(8):991-1006. doi: 10.2174/0118715303260423231122111705.
2
Italian Guidelines for the Management of Non-Functioning Benign and Locally Symptomatic Thyroid Nodules.意大利非功能性良性及局部有症状甲状腺结节管理指南。
Endocr Metab Immune Disord Drug Targets. 2023;23(6):876-885. doi: 10.2174/1871530323666230201104112.
3
Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment.意大利成人超重和肥胖以及代谢合并症管理指南,这些合并症对行为治疗有抵抗性。
J Endocrinol Invest. 2024 Jun;47(6):1361-1371. doi: 10.1007/s40618-024-02361-y. Epub 2024 Apr 17.
4
Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy.意大利骨质疏松症的诊断、预防及治疗指南。
Clin Cases Miner Bone Metab. 2012 Sep;9(3):170-8. Epub 2012 Dec 20.
5
Does renal function improve after parathyroidectomy in primary hyperparathyroidism?原发性甲状旁腺功能亢进症患者行甲状旁腺切除术后肾功能会改善吗?
Nefrologia (Engl Ed). 2019 Mar-Apr;39(2):160-167. doi: 10.1016/j.nefro.2018.08.007. Epub 2018 Nov 17.
6
Parathyroidectomy for adults with primary hyperparathyroidism.甲状旁腺切除术治疗原发性甲状旁腺功能亢进症成人患者。
Cochrane Database Syst Rev. 2023 Mar 8;3(3):CD013035. doi: 10.1002/14651858.CD013035.pub2.
7
Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.原发性甲状旁腺功能亢进症:关于评估、诊断和管理的综述与建议。加拿大及国际共识。
Osteoporos Int. 2017 Jan;28(1):1-19. doi: 10.1007/s00198-016-3716-2. Epub 2016 Sep 9.
8
Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa.2009 年至 2021 年原发性甲状旁腺功能亢进症的特征、治疗及预后:南非单中心报告。
BMC Endocr Disord. 2024 Apr 25;24(1):53. doi: 10.1186/s12902-024-01583-8.
9
Clinical presentation and management of patients with primary hyperparathyroidism in Italy.意大利原发性甲状旁腺功能亢进症患者的临床表现和治疗。
J Endocrinol Invest. 2018 Nov;41(11):1339-1348. doi: 10.1007/s40618-018-0879-z. Epub 2018 Apr 3.
10
Primary hyperparathyroidism in adults-(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society.成人原发性甲状旁腺功能亢进症(第 I 部分)评估和医学管理:澳大利亚内分泌学会、澳大利亚和新西兰内分泌外科医生以及澳大利亚和新西兰骨与矿物质学会的立场声明。
Clin Endocrinol (Oxf). 2024 Jan;100(1):3-18. doi: 10.1111/cen.14659. Epub 2021 Dec 21.

引用本文的文献

1
Estimated fracture risk in osteopenic patients with primary hyperparathyroidism.原发性甲状旁腺功能亢进症骨质疏松患者的骨折风险估计
Endocrine. 2025 Sep 10. doi: 10.1007/s12020-025-04406-5.
2
Uric Acid in Primary Hyperparathyroidism: Marker, Consequence, or Bystander?原发性甲状旁腺功能亢进症中的尿酸:标志物、后果还是旁观者?
Metabolites. 2025 Jul 2;15(7):444. doi: 10.3390/metabo15070444.
3
Trabecular bone score as a possible new surgical recommendation in patients with asymptomatic primary hyperparathyroidism.小梁骨评分作为无症状原发性甲状旁腺功能亢进患者一种可能的新手术推荐指标。
J Endocrinol Invest. 2025 Apr 25. doi: 10.1007/s40618-025-02590-9.

本文引用的文献

1
Multi-modality parathyroid imaging: A shifting paradigm.多模态甲状旁腺成像:一种不断变化的模式。
World J Radiol. 2023 Mar 28;15(3):69-82. doi: 10.4329/wjr.v15.i3.69.
2
Does Surgeon Volume Impact Morbidity Following Parathyroidectomy? A Study of 16,140 Parathyroidectomies from the UK Registry of Endocrine and Thyroid Surgery (UKRETS) Database.外科医生的手术量会影响甲状旁腺切除术后的发病率吗?一项基于英国内分泌与甲状腺外科注册数据库(UKRETS)中16140例甲状旁腺切除术的研究。
World J Surg. 2023 May;47(5):1221-1230. doi: 10.1007/s00268-022-06863-9. Epub 2023 Jan 2.
3
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism.原发性甲状旁腺功能亢进的流行病学、病理生理学和遗传学。
J Bone Miner Res. 2022 Nov;37(11):2315-2329. doi: 10.1002/jbmr.4665. Epub 2022 Oct 17.
4
Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop.原发性甲状旁腺功能亢进的评估与管理:第五次国际研讨会总结声明和指南。
J Bone Miner Res. 2022 Nov;37(11):2293-2314. doi: 10.1002/jbmr.4677. Epub 2022 Oct 17.
5
Classical and Nonclassical Manifestations of Primary Hyperparathyroidism.原发性甲状旁腺功能亢进的经典和非经典表现。
J Bone Miner Res. 2022 Nov;37(11):2330-2350. doi: 10.1002/jbmr.4679. Epub 2022 Oct 17.
6
Management of Primary Hyperparathyroidism.原发性甲状旁腺功能亢进症的治疗。
J Bone Miner Res. 2022 Nov;37(11):2391-2403. doi: 10.1002/jbmr.4682. Epub 2022 Oct 17.
7
Surgical Aspects of Primary Hyperparathyroidism.原发性甲状旁腺功能亢进的手术治疗。
J Bone Miner Res. 2022 Nov;37(11):2373-2390. doi: 10.1002/jbmr.4689. Epub 2022 Oct 17.
8
The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.原发性甲状旁腺功能亢进症患者的药物和手术治疗的疗效和安全性:一项随机对照试验的系统评价和荟萃分析。
J Bone Miner Res. 2022 Nov;37(11):2351-2372. doi: 10.1002/jbmr.4685. Epub 2022 Oct 17.
9
Long-term outcome of surgical techniques for sporadic primary hyperparathyroidism in a tertiary referral center in Belgium.比利时一家三级转诊中心散发性原发性甲状旁腺功能亢进症手术治疗的长期结果。
Langenbecks Arch Surg. 2022 Nov;407(7):3045-3055. doi: 10.1007/s00423-022-02660-z. Epub 2022 Sep 1.
10
Calcium Challenge to Confirm Secondary Hyperparathyroidism Caused by Decreased Calcium Intake.钙挑战以确认因钙摄入减少引起的继发性甲状旁腺功能亢进。
Endocr Pract. 2022 Oct;28(10):1069-1071. doi: 10.1016/j.eprac.2022.07.009. Epub 2022 Jul 21.

意大利散发性原发性甲状旁腺功能亢进症管理指南。

Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism.

机构信息

Endocrinology Unit, Azienda Sanitaria-Universitaria Friuli Centrale, P.O. Santa Maria della Misericordia, Udine, Italy.

Department of Endocrinology, Diabetes and Metabolism, Ospedale Santa Croce and Carle Hospital, Cuneo, Italy.

出版信息

Endocr Metab Immune Disord Drug Targets. 2024;24(8):991-1006. doi: 10.2174/0118715303260423231122111705.

DOI:10.2174/0118715303260423231122111705
PMID:38644730
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11165713/
Abstract

AIM

This guideline (GL) is aimed at providing a clinical practice reference for the management of sporadic primary hyperparathyroidism (PHPT) in adults. PHPT management in pregnancy was not considered.

METHODS

This GL has been developed following the methods described in the Manual of the Italian National Guideline System. For each question, the panel appointed by Associazione Medici Endocrinology (AME) and Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS) identified potentially relevant outcomes, which were then rated for their impact on therapeutic choices. Only outcomes classified as "critical" and "important" were considered in the systematic review of evidence. Those classified as "critical" were considered for the clinical practice recommendations.

RESULTS

The present GL provides recommendations about the roles of pharmacological and surgical treatment for the clinical management of sporadic PHPT. Parathyroidectomy is recommended in comparison to surveillance or pharmacologic treatment in any adult (outside of pregnancy) or elderly subject diagnosed with sporadic PHPT who is symptomatic or meets any of the following criteria: • Serum calcium levels >1 mg/dL above the upper limit of normal range. • Urinary calcium levels >4 mg/kg/day. • Osteoporosis disclosed by DXA examination and/or any fragility fracture. • Renal function impairment (eGFR <60 mL/min). • Clinic or silent nephrolithiasis. • Age ≤50 years. Monitoring and treatment of any comorbidity or complication of PHPT at bone, kidney, or cardiovascular level are suggested for patients who do not meet the criteria for surgery or are not operated on for any reason. Sixteen indications for good clinical practice are provided in addition to the recommendations.

CONCLUSION

The present GL is directed to endocrinologists and surgeons - working in hospitals, territorial services or private practice - and to general practitioners and patients. The recommendations should also consider the patient's preferences and the available resources and expertise.

摘要

目的

本指南(GL)旨在为成人散发性甲状旁腺功能亢进症(PHPT)的管理提供临床实践参考。未考虑妊娠期间的 PHPT 管理。

方法

本 GL 遵循意大利国家指南系统手册中描述的方法制定。对于每个问题,由 Associazione Medici Endocrinology(AME)和 Società Italiana dell'Osteoporosi、del Metabolismo Minerale e delle Malattie dello Scheletro(SIOMMMS)任命的专家组确定潜在相关的结局,然后对这些结局对治疗选择的影响进行评分。只有被归类为“关键”和“重要”的结局才会在证据的系统回顾中进行考虑。被归类为“关键”的结局将被用于临床实践建议。

结果

本 GL 提供了关于药物治疗和手术治疗在散发性 PHPT 临床管理中的作用的建议。与监测或药物治疗相比,甲状旁腺切除术推荐用于任何患有散发性 PHPT 的成年(妊娠除外)或老年患者,这些患者有症状或符合以下任何标准:

  • 血清钙水平比正常范围上限高出 1 毫克/分升以上。

  • 尿钙水平>4 毫克/公斤/天。

  • DXA 检查显示骨质疏松症和/或任何脆性骨折。

  • 肾功能受损(eGFR<60 毫升/分钟)。

  • 临床或无症状的肾结石。

  • 年龄≤50 岁。

对于不符合手术标准或因任何原因未接受手术的患者,建议监测和治疗 PHPT 在骨骼、肾脏或心血管水平的任何合并症或并发症。除了建议之外,还提供了十六项良好临床实践的指征。

结论

本 GL 面向在医院、地区服务或私人诊所工作的内分泌学家和外科医生,以及全科医生和患者。建议还应考虑患者的偏好以及可用的资源和专业知识。